Kornimate/medical-research-clean huggingface dataset:
psychological impact of tooth loss

Conditions: Edentulous Mouth; Partial Edentulism

Summary: tooth loss impact on daily living, mood and self-perceived well-being. however, psychological impact of teeth loss has not been evaluated. present study aims to evaluate the psychological conditions of patients pending complete tooth extraction before and shortly after tooth loss using hospital anxiety and depression scale (had) and geriatric oral health assessment index (gohai).

patients will be interviewed concerning their psychological conditions (hads) and their oral health related quality of life (gohai) before tooth extraction and one month after complete tooth loss.

Eligibility criteria:
inclusion criteria: * willing to participate to the study * dental status identified exclusion criteria: * uncooperative ou patient not able to complete the questionary * adult patients under protection

Keywords: tooth loss, edentulousness, psychology, oral health-related
an observational study in patients with her2 positive metastatic breast cancer (systhers registry)

Conditions: Breast Cancer

Summary: this multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with her2-positive (her2+) metastatic breast cancer (mbc). eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. data will be collected for up to 8 years.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * initial diagnosis of her2+ mbc, as diagnosed by the treating physician, no more than 6 months prior to study enrollment * availability of cancer-specific historical data points in the patient's medical records exclusion criteria: * any inability to provide informed consent
nutrition, exercise, and technology for weight loss

Conditions: Overweight; Obesity

Summary: the purpose of this study is to evaluate whether a social support-enhanced, technology-based, behavioral weight control intervention can improve weight loss over existing best practices.

this 4-month randomized controlled trial is designed to investigate the short-term efficacy and feasibility of a novel, social support-enhanced behavioral weight control intervention. participants will be recruited via email listservs, fliers, and word of mouth. they will be randomized to a standard behavioral weight control treatment (sbt) or a social support-enhanced behavioral weight control treatment which receives the same intervention as sbt plus social support resources (specifically, additional self-monitoring technologies) for weight loss.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 25 kg/m2 and 55 kg/m2 * age 18 years or older * access to a computer with an internet connection * smartphone ownership (android or ios) * willing to be randomized to either one of the two study groups * only one member of the same household eligible to participate exclusion criteria: * currently lactating, pregnant, or planning to become pregnant during the length of the study * been diagnosed with type 1 or type 2 diabetes * medical or physical contraindications or limitations for engaging in physical activity * history of major medical or psychiatric conditions * recent changes in medication known to affect weight * schedule that would prohibit or restrict attendance at a designated time for weekly in- person group meetings * currently participating in a weight management program * currently on medication that might affect weight loss
perceptions of vaping products

Conditions: Abuse Tobacco; Exposure

Summary: this clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.

primary objectives: i. assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes. ii. assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine. iii. determine the impact of metatine on e-cigarette puffing behavior (topography). outline: participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. participants must also undergo 4 blood draws during the vaping session.

Eligibility criteria:
inclusion criteria: * aged 21-34 years * current nicotine ec user (defined as ≥ weekly use over the past 3 months) * willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions * read and speak english exclusion criteria: * recently coronavirus disease 2019 (covid-19) positive (defined as a positive test in the past 30 days) or a recent covid-19 hospitalization (defined as a hospitalization within the past 6 months) * unstable or significant psychiatric conditions (past and stable conditions will be allowed) * history of cardiac event or distress within the past 3 months * have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days * are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test) * have hemophilia or another type of bleeding disorder * are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
rpms compared with pelvic floor exercises for treatment of urinary incontinence

Conditions: Urinary Incontinence

Summary: this study will compare the clinical efficacy and safety between rpms device and pelvic floor exercises for the treatment of urinary incontinence. the subjects will be enrolled and assigned into two study groups - active and control group. subjects will be required to complete six (6) treatment visits and five follow-up visits - 1, 3, 6, 9 and 12 months after the final treatment.


Eligibility criteria:
inclusion criteria: * female aged 25-70 years * suffers from specific types of ui - stress urinary incontinence (sui), urge urinary incontinence (uui) and/or mixed urinary incontinence (mui) * voluntarily signed informed consent form * subjects willing and able to abstain from partaking in any treatment of urinary incontinence other than the study procedure * subjects currently undergoing any treatment for stress, urge and/or mixed urinary incontinence, have to undergo a two-week wash-out period before start of the study exclusion criteria: * use of botox® in the bladder or pelvic muscles in the last year * use of interstim® or similar device for the treatment of ui * suffers from other types of urinary incontinence other than sui, uui, mui * pelvic organ prolapse grade 2 and higher * pronounced lesions of the pudendus nerve during clinical neurophysiological examination * currently lactating * cardiac pacemakers * implanted defibrillators and/or neurostimulators * electronic implants * metal implants, including copper iud * drug pumps * hemorrhagic conditions * anticoagulation therapy * fever * pregnancy * following recent surgical procedures when muscle contraction may disrupt the healing process * application over areas of the skin which lack normal sensation * any disorders that the investigator deems would interfere with study endpoints or subject safety
challenges and concerns faced by parents of children with cleft lip and/or palate

Conditions: Cleft Lip and Palate

Summary: cleft lip and/or palate (clp) are the most common oro-facial congenital anomalies. these anomalies have an impact on feeding, speech and speech development, facial aesthetics \& oral health, all of which are factors that heavily impact the quality of life of clp patients. clp also has an effect on the families' social and psychological health. qualitative research helps understand the perspectives of the participants by exploring the psycho-social aspects of care. phenomenological approach is a qualitative research method that aims to borrow participants' lived experiences to better understand a specific phenomenon. currently, there is no clear understanding of the fears, anxieties, and challenges faced by parents of clp patients in egypt.


Eligibility criteria:
inclusion criteria: * parents of patients with non-syndromic clp. exclusion criteria: * parents of patients presenting with dental pain.

Keywords: cleft lip and palate challenges concerns
study00015328: sepsis endotypes

Conditions: Sepsis

Summary: determine the utility of biomarkers measured in blood and body fluid (stool, saliva, tracheal aspirate) when combined with clinical data, for predicting sepsis phenotypes that are associated with poor clinical outcomes. we hypothesize that resistin is a biomarker which provides critical prognostic information when used in conjunction with standard clinical data, in patients with sepsis and septic shock.

day 1 sample collection: 20ml of blood for chemical and genetic biomarker analysis. ≤1ml of saliva, stool, and tracheal aspirate for inflammatory marker analysis. quadratus lumborum muscle size measurement and ct abdomen correlation. if not part of routine care, additional blood tests for cell differential, procalcitonin, and inflammatory markers. electronic medical records (emr) data: apache ii and sofa severity scores. demographics, vital signs, inflammatory markers, organ dysfunction markers, and various blood chemistry values. days 2-3 daily documentation: record the most abnormal value for the same parameters as day 1. days 3-5 (once) sample collection: repeat of blood, saliva, stool, and tracheal aspirate collection. emr data access for severity scores and other clinical parameters. days 5-6 daily documentation: continued recording of the most abnormal values for clinical parameters. days 7-10 (once) sample collection: repeat of blood, saliva, stool, and tracheal aspirate collection. measurement of muscle size and ct correlation. emr data access for the same parameters as earlier. day 14 (or discharge) final sample collection: 20ml of blood and other samples, with no more than 1 ml/kg of blood collected over the entire study. emr and clinical data: collection of severity scores, vital signs, inflammation markers, organ dysfunction markers, and other clinical variables. day 30, 3 months, 6 months, and 1 year long-term outcomes: emr review for clinical outcomes such as date of death, re-hospitalization, persistent critical illness. phone interviews to gather subjective data about the post-hospitalization course and complications.

Eligibility criteria:
inclusion criteria: 1. adults (age ≥ 18 ) 2. gender: male or female 3. cognitively intact or impaired patients, given that sepsis may cause a certain degree of cognitive dysfunction in patients. all patients in the control group (no sepsis) will be cognitively intact 4. clinical suspicion for sepsis (except for control/comparison group for whom infection is not a current concern) exclusion criteria: 1. patients with hematologic malignancies 2. pregnant women 3. patient/surrogate is not fluent in english and no translation services are available 4. long-term immunosuppressive therapy 5. prisoner
testing a personalize medication log for patients with lymphoma

Conditions: Lymphoma

Summary: the purpose of this study is to see if using the medlog is helpful to patients. since the investigators do not yet know if this medlog is helpful, some patients will receive it and some will receive our standard of care. the investigators want to know whether providing patients with this additional information is helpful and if having this additional information about their treatment schedule has an effect on their quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of lymphoma * no prior treatment for lymphoma * scheduled to receive chop14 +/- rituximab, ceop 21, chope or epoch +/- rituximab * age 18 or older * able to speak and read english exclusion criteria: * documented major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.

Keywords: medication log 15-008
implitapide in patients with homozygous familial hypercholesterolemia (hofh) on maximal concurrent lipid-lowering therapy

Conditions: Familial Hypercholesterolemia

Summary: the purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (ldl-c) in patients with homozygous familial hypercholesterolemia (hofh).


Eligibility criteria:
inclusion criteria: in order to participate in this study, patients must meet all of the following inclusion criteria: * be between 8 and 70 years old with a diagnosis of hofh; * be stable on and maintain concomitant therapy with hypolipidemic drugs or treatments; * have an appropriate calculated, fasting ldl-c levels and an appropriate triglyceride (tg) level; * be male or nonpregnant, nonlactating female; * give informed consent; and * meet body weight and height requirements. exclusion criteria: in order to participate in this study, patients must not meet any of the following exclusion criteria: * recent myocardial infarction, percutaneous transluminal coronary intervention, coronary artery bypass graft surgery, or cerebrovascular accident; * uncontrolled hypothyroidism or other uncontrolled endocrine disease; * known, clinically significant eye abnormalities (e.g., cataracts); * appropriate serum creatinine phosphokinase levels; * history of liver disease or liver enzyme levels above appropriate levels; * alkaline phosphatase above appropriate levels; * liver cirrhosis and severe liver steatosis; * clinically significant infection, malignancy, or psychosis; * use of oral anticoagulants or digoxin, unless the dose has been stable for 4 weeks; * participation in any other investigational study, including device or observational studies, within 30 days; * lactating or have a positive serum pregnancy test; * history of or current drug or alcohol abuse; or * unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator.

Keywords: homozygous familial hypercholesterolemia (hofh)
blueberry effects on dark vision and glare recovery

Conditions: Blindness and Low Vision

Summary: clinical evidence for effects of plant anthocyanins on vision, and particularly night vision is controversial. two clinical trials were conducted to investigate whether blueberry juice consumption affected visual dark adaptation, functional night vision, and recovery after photo-bleaching of the retina. one trial (s2) employed a 3 week intervention and washout period, and two doses of blueberries plus a placebo. the other trial (l1) employed a 12 week intervention plus an 8 week washout and tested one blueberry juice dose against a juice placebo.

vision tests: 1. dark adaptometry, 2. scotopic visual acuity, 3. scotopic contrast sensitivity, 4. rod/cone conversion, 5. recovery after retinal photobleaching

Eligibility criteria:
inclusion criteria: * visual acuity better than 6/7.5 on edtrs acuity chart at 2.5m * visual contrast sensitivity within normal range at 2.5m as tested on visteck 3000 * stereo acuity better than 80 seconds of arc on frisby stereoacuity test * no ocular history other than refractive glasses * no family history of eye disease exclusion criteria: * family history of retinal degeneration, glaucoma, diabetes, hypertension, cataract, or amblyopia (dimness in vision). * evidence in subject (upon examination) of amblyopia (dimness in vision), manifest strabismus (unable to focus both eyes on one spot), or anisotropia (non-uniform responsiveness between both eyes). * intraocular pressure above 21mmhg from an average of three measures using mentor tonopen-xl

Keywords: blueberry anthocyanin dark vision photo bleaching visual perception photic stimulation
predictors of post operative morbidity in older women with pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: the investigators hypothesize that functional status scores in elderly women undergoing surgery for pelvic organ prolapse will be lower at 6 weeks post-operatively but will have returned to baseline at 12 weeks post-operatively. the investigators hypothesize that greater co-morbidity, frailty and worse functional status before surgery are associated with slower functional recovery, prolonged length of stay in a hospital or nursing care institution and greater post-operative complications following surgery for pelvic organ prolapse.

an increasing number of elderly women are undergoing surgical treatment for pelvic organ prolapse (pop). based on us census data1 and the estimated prevalence of pelvic organ prolapse in women 60 and over, an estimated 1.6 million women over 60 are currently affected with pelvic organ prolapse (pop). this number is expected to increase to 3.4 million by 2050. prior studies show that geriatric patients have unique physiologic vulnerability, and elderly women undergoing surgery are at risk for worse post-operative outcomes than younger women. however, data from the urogynecology literature are conflicting. some studies show an increased risk for complications as women age while other studies show no significant increased risk. other evidence suggests that elderly women still are below their baseline quality-of-life status 6 weeks post-operatively. return to baseline functional status at 6 weeks post-operatively was not improved when these women were randomized to enhanced pre-operative geriatric assessment versus routine care. these studies were limited by low numbers of very old women and women undergoing obliterative surgery, usually recommended for women with higher co-morbidities and lower functional status. post-operative outcomes have been traditionally measured in terms of medically documented complications such as infection, organ injury, cardiac and pulmonary complications. however, studies from other surgical specialties suggest that older subjects undergoing surgery can suffer from significant worsening of functional status resulting in disability, need for long-term care, and dependency at home. objective markers of functional status, co-morbidity and frailty are potential useful predictors of post-operative complications following surgery in the elderly. however, there is lack of data on the functional status of elderly women undergoing pop surgery, as well as on factors influencing recovery from surgery. the goal of our study is to explore the utility of pre-operative markers of functional status, co-morbidities and frailty to explain post-operative morbidities in elderly women undergoing surgical treatment for pelvic organ prolapse.

Eligibility criteria:
inclusion criteria: * women over age 60 undergoing either reconstructive or obliterative surgery (for stage 2 or greater pop 2) english speaking exclusion criteria: * women under the age of 60 will be excluded.
para-aortic prophylactic irradiation for locally advanced cervical cancer

Conditions: Cervical Cancer

Summary: para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. the aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.

this clinical trial enrolled participants with locally advanced cervical cancer with positive pelvic lymph nodes below the common iliac region diagnosed by positron emission tomography-computed tomography(pet-ct). participants should be able to receive concurrent cisplatin chemotherapy. no anti-tumor treatment was given before randomization. participants will be randomly assigned to two groups. the study group will receive radiotherapy of pelvic and para-aorta, concurrent chemotherapy and brachytherapy, and the control group will receive pelvic radiotherapy, concurrent chemotherapy and brachytherapy.

Eligibility criteria:
inclusion criteria: * the patients voluntarily participated in the study and signed the informed consent * 18-75 female * cervical squamous cell carcinoma / adenocarcinoma / adenosquamous cell carcinoma * according to international federation of gynecology and obstetrics(figo) 2009 stage, stage ⅰb2 - ⅳa with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes diagnosed by pet-ct * cisplatin chemotherapy is acceptable * eastern cooperative oncology group(ecog) score 0-1 * the expected survival was more than 6 months * women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate contraceptive methods during the test * according to the judgment of the researcher, those who can comply with the trial protocol exclusion criteria: * uncontrolled severe infection * combined with other malignant tumor patients who need treatment and / or new diagnosis within 5 years * the patient has received anti-tumor treatment * liver cirrhosis, decompensated liver disease, chronic renal insufficiency and renal failure * history of immunodeficiency, including hiv positive or other acquired congenital immunodeficiency disease * myocardial infarction, severe arrhythmia and grade 2 or more congestive heart failure (nyha classification) * patients with previous pelvic artery embolization * previous radiotherapy for pelvic malignant tumor * there was a history of severe allergic reaction to platinum containing chemotherapy drugs * complications, need to be taken during the treatment of liver and kidney function damage drugs, such as tuberculosis * the patients who could not understand the content of the experiment and could not cooperate and refused to sign the informed consent * patients with accompanying diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study

Keywords: locally advanced cervical cancer para-aortic radiotherapy concurrent radiochemotherapy pet-ct